Overall survival and survival with intervention-free sustained engraftment stratified based on alemtuzumab and CXCL9 levels. Overall survival stratified based on day 0 alemtuzumab levels (A), day +14 CXCL9 levels (C), and day +28 CXCL9 levels (E). Probability of survival with intervention-free sustained engraftment stratified based on day 0 alemtuzumab levels (B), day +14 CXCL9 levels (D), and day +28 CXCL9 levels (F).